The Phase 3 ELRiSE MF trial initiation de-risks the elritercept program and triggers a $20M milestone, with 25% of net proceeds earmarked for shareholder return. Monitor enrollment updates and any subsequent milestone announcements from Takeda, as the total potential deal value exceeds $1.1 billion.
Price Chart
Executive Summary
Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by first patient dosing in the Phase 3 ELRiSE MF trial of elritercept in myelofibrosis with anemia. The company expects to distribute 25% of net proceeds from this payment to stockholders, adding a modest capital return element to a positive clinical de-risking event.
Key Facts
- $20 million development milestone payment triggered by first patient dosed in Phase 3 ELRiSE MF trial
- ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial comparing elritercept to placebo in myelofibrosis patients with anemia on concurrent ruxolitinib therapy
- Keros received a $200 million upfront cash payment from Takeda in February 2025 under the global license agreement
- Keros is eligible for development, commercial, and sales milestones with potential to exceed $1.1 billion, plus tiered royalties on net sales
- Keros expects to distribute 25% of net cash proceeds from this milestone payment to stockholders
- The license agreement with Takeda covers worldwide rights outside mainland China, Hong Kong, and Macau
Financial Impact
$20 million milestone payment; 25% of net proceeds to be distributed to stockholders
Risk Factors
- Clinical trial enrollment delays could slow future milestone triggers
- Clinical trial results remain binary — Phase 3 failure would impair remaining milestone and royalty value
- Distribution of 25% of net proceeds is modest relative to market cap and does not signal a sustained capital return program
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000059 |
| Exhibit: exhibit99192926pr.htm | 0001664710-26-000059 |
| Document: 0001664710-26-000059-index-headers.html | 0001664710-26-000059 |
| Document: 0001664710-26-000059-index.html | 0001664710-26-000059 |
| Document: 0001664710-26-000059.txt | 0001664710-26-000059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $11.37 | awaiting T+20 | — | $11.43 (+0.48%) |
Sep 29, 2026 28d ago | 8-K | $11.19 $11.43 | ▲ +2.10% | ▲ +1.39% | $11.43 (+2.10%) |
Sep 28, 2026 29d ago | 8-K | $11.28 $11.33 | ▲ +0.44% | ▲ +0.47% | $11.43 (+1.29%) |
Sep 28, 2026 29d ago | Press Release | $11.28 $11.33 | ▲ +0.44% | ▲ +0.47% | $11.43 (+1.29%) |
Sep 17, 2026 5w ago | EFFECT | $11.36 $11.10 | ▼ −2.29% | ▼ −3.49% | $11.43 (+0.57%) |
Sep 8, 2026 7w ago | 8-K | $11.31 $11.21 | ▼ −0.88% | ▼ −3.08% | $11.43 (+1.02%) |
Aug 20, 2026 9w ago | Insider Cluster | $11.03 $11.48 | ▲ +4.08% | ▲ +3.06% | $11.43 (+3.58%) |
Aug 3, 2026 12w ago | 8-K | $10.25 $11.07 | ▲ +8.00% | ▲ +9.24% | $11.43 (+11.46%) |
Aug 3, 2026 12w ago | Press Release | $10.25 $11.07 | ▲ +8.00% | ▲ +9.24% | $11.43 (+11.46%) |
Jul 30, 2026 12w ago | 8-K | $10.07 $11.03 | ▲ +9.53% | ▲ +6.55% | $11.43 (+13.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers